Compare Gigacloud Technology Inc (GCT) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gigacloud Technology Inc vs Heron Therapeutics Inc — how do they compare? Gigacloud Technology Inc trades at $57.21 (market cap $2.02B), while Heron Therapeutics Inc trades at $0.4 (market cap $68.01M). The key difference: Gigacloud Technology Inc is far larger — about 29.7× Heron Therapeutics Inc's market cap, and Gigacloud Technology Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gigacloud Technology Inc for 21 Days and Heron Therapeutics Inc for 35 Days on average.
| GCT | HRTX | |
|---|---|---|
Market Cap | $2.02B | $68.01M |
Volume | 1,020,985 | 1,891,941 |
Sector | Technology | Health |
52-Week High | $56.42 | $1.49 |
52-Week Low | $25.46 | $0.27 |
Typical Hold Time | 21 Days | 35 Days |
Enterprise Value | $2.14B | $174.75M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GCT trades at $57.02, up 1.89% today, showing strong momentum with consistent earnings beats in recent quarters. The stock exhibits bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid profitability with 10.65% net margins and robust ROE of 32.34%. Recent news highlights institutional interest and European expansion driving growth.
Outlook remains positive with analyst consensus favoring buys (66.7%) and revenue projected to grow to $1.5B in 2026. Key risks include insider selling and competitive pressures in consumer discretionary sector. The stock trades at reasonable valuation multiples (P/E 13.44) with upside potential to consensus target of $32.50.
HRTX trades at $0.3967, up 1.72% today, with a bullish technical signal from moving averages but mixed earnings. The company reported a net loss of $20.20 million in 2025, with revenue of $154.90 million, and has a high gross margin of 70.07% but negative profitability metrics. Recent Q2 2026 results missed EPS estimates, though Q4 2025 beat expectations. Analyst consensus is strongly bullish with 17 buy ratings.
The outlook is cautious due to persistent losses and cash burn, but strong analyst support and a low P/S ratio of 0.44 may appeal to value investors. Key risks include ongoing unprofitability and competitive pressures in the biotech sector. Investors should weigh the high institutional optimism against fundamental challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
